From ASTRO 2020
- In patients with cervical cancer who receive radiotherapy after undergoing hysterectomy, image-guided intensity-modulated radiotherapy (IG-IMRT) significantly lowers the risk for late gastrointestinal toxicity vs 3-dimensional conformal radiotherapy (3D-CRT).
- No difference in disease-free survival was seen between the treatments.
Why this matters
- Results support IG-IMRT as the new standard of care for postoperative pelvic radiation therapy in this setting.
- Final analysis of phase 3 PARCER trial.
- 300 patients with cervical cancer underwent hysterectomy and were randomly assigned to IG-IMRT (n=151) and 3D-CRT (n=149) as part of adjuvant chemoradiotherapy.
- Funding: Department of Atomic Energy, India; Varian International; the Terry Fox Foundation.
- Median follow-up was 49 months.
- At 4 years, in the IG-IMRT and 3D-CRT groups, respectively:
- Grade ≥2 late gastrointestinal adverse event (AE) rates were 19.2% and 36.2% (HR, 0.53; P=.005).
- Grade ≥3 late gastrointestinal AE rates were 2.0% and 8.7% (HR, 0.23; P<.01>
- Rates of acute grade ≥2 diarrhea were 17.2% and 27.2% (P=.004).